Proteotoxic stress targeted therapy (PSTT)

Oncotarget

Volumn 2, Issue 5, 2011, Pages 356-357

  Sherman, Michael Y ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CHAPERONE; HEAT SHOCK PROTEIN 27; HEAT SHOCK TRANSCRIPTION FACTOR 1; PUROMYCIN; SMALL INTERFERING RNA; BORONIC ACID DERIVATIVE; HEAT SHOCK PROTEIN; PROTEASOME; PYRAZINE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; NOTE; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR MICROENVIRONMENT; ANIMAL; APOPTOSIS; CELL PROTECTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; GENETICS; HUMAN; HYPERTHERMIC THERAPY; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROTEIN FOLDING;

ANIMALS; APOPTOSIS; BORONIC ACIDS; COMBINED MODALITY THERAPY; CYTOPROTECTION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HEAT-SHOCK PROTEINS; HUMANS; HYPERTHERMIA, INDUCED; MOLECULAR CHAPERONES; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; PYRAZINES;

EID: 80053405797     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.284     Document Type: Note

References (18)

1. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007;67(4):1783-92.
2. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107(12):4907-16.
3. Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005;4(4):686-92.
4. Lanneau D, Wettstein G, Bonniaud P, Garrido C. Heat shock proteins: cell protection through protein triage. ScientificWorldJournal;10:1543-52.
5. Chauhan D, Li G, Auclair D, et al. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis 2004;9(2):149-55.
6. Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 Overcomes Bortezomib/Proteasome Inhibitor PS-341 Resistance in Lymphoma Cells. Cancer Res 2003;63(19):6174-7.
7. Nakamura T, Lipton SA. Cell death: protein misfolding and neurodegenerative diseases. Apoptosis 2009;14(4):455-68.
8. Solimini NL, Luo J, Elledge SJ. Non-Oncogene Addiction and the Stress Phenotype of Cancer Cells. Cell 2007;130(6):986-8.
9. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006;31(3):164-72.
10. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007;130(6):1005-18.
11. Min JN, Huang L, Zimonjic DB, Moskophidis D, Mivechi NF. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 2007;26(35):5086-97.
12. Meng L, Hunt C, Yaglom JA, Gabai VL, Sherman MY. Heat shock protein Hsp72 plays an essential role in Her2-induced mammary tumorigenesis. Oncogene.
13. Calderwood SK, Ciocca DR. Heat shock proteins: stress proteins with Janus-like properties in cancer. Int J Hyperthermia 2008;24(1):31-9.
14. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007;6(1):299-308.
15. Matsui Y, Hadaschik BA, Fazli L, Andersen RJ, Gleave ME, So AI. Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. Mol Cancer Ther 2009;8(8):2402-11.
16. Zaarur N, Gabai VL, Porco JA Jr, Calderwood S, Sherman MY. Targeting Heat Shock Response to Sensitize Cancer Cell to Proteasome and Hsp90 Inhibitors. Cancer Research 2006;66(3):1783-91.
17. Neznanov N, Gorbachev AV, Neznanova L, et al. Antimalaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle 2009;8(23):3960-70.
18. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget. 2011;2(3):209-21.